Skip to main content
Premium Trial:

Request an Annual Quote

Taconic to Sell Medicyte's Hepatocyte Cell Strains

NEW YORK (GenomeWeb News) – Taconic and Medicyte announced a sales and marketing agreement covering Medicyte's products.

Under the terms of the deal, Taconic will promote and sell Medicyte's human primary Upcyte hepatocyte cell strains and corresponding media, which have been developed for in vitro applications. According to the companies, the deal strengthens Taconic's tADMET portfolio of models, and expands Medicyte's distribution and market visibility, while at the same time providing entry into new markets for its hepatocyte cell strains.

The tADMET products are genetically and tissue humanized mouse cells and in vitro tools and services for improving the predictability of drug response in humans. Translational research applications for tADMET include studies in drug metabolism, toxicology and safety, and infectious diseases of the liver.

Financial and other terms of the deal were not disclosed.

"Human hepatocytes are indispensable for many applications in research, drug screening, and development," Joris Braspenning, managing director of Medicyte, said in a statement. "However, the availability of primary human hepatocytes is limited and their quality is variable. With the Upcyte hepatocytes, we can bring predictive, reliable, and standardized cells on the market to close the gap."

Medicyte, based in Heidelberg, Germany, develops controlled, scalable, and standardized human primary cell products. Taconic, located in New York's Hudson River Valley, provides genetically engineered mouse and rat models and services.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.